Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Presents Protein Biomarker Study Supporting OVA2 Ovarian Cancer Test


Vermillion this week showed preliminary data from its work with Johns Hopkins University School of Medicine to identify protein biomarkers that could improve the accuracy of its OVA1 test for ovarian cancer.

According to the company, the study, which was presented at the 42nd Annual Meeting on Women's Cancer of the Society of Gynecological Oncologists, examined more than 20 candidate biomarkers, identifying three that added information to CA125, the protein biomarker conventionally used in ovarian cancer diagnosis.

This next-generation version of the test, called OVA2, has been a recent area of focus for Vermillion, with CEO Gail Page during a Q4 earnings call citing it – along with the company's vascular disease diagnostic Vasclir – as one of the key products in its pipeline.

In the registration statement filed with the US Securities and Exchange Commission for a recent $21.8 million public offering, Vermillion noted that the proceeds would be used in part to accelerate trials of OVA2 (GWDN 2/15/2011). In November, the firm received $488,958 through the Qualifying Therapeutic Discovery Project Program to be used in part for the development of the test (PM 11/5/2010).

The OVA2 studies presented this week were conducted by Johns Hopkins professor Zhen Zhang and professor and director of the university's Biomarker Discovery Center Daniel Chan.

"Markers that can improve the clinical specificity of current tools for ovarian cancer detection will enhance our ability to test patients in whom cancer is suspected," Vermillion's chief science officer Eric Fung said in a statement. "These results pave the way for further studies that could lead to additional novel tests in the ovarian cancer space."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.